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SwellingIn humans, chikungunya virus (CHIKV) infection causes fever, rash, and acute and persisting polyarthralgia/
arthritis associated with joint swelling. We report a new CHIKV disease model in adult mice that distin-
guishes the wild-type CHIKV-LR strain from the live-attenuated vaccine strain (CHIKV-181/25). Although
eight-week old normal mice inoculated in the hind footpad developed no hind limb swelling with either
virus, CHIKV-LR replicated in musculoskeletal tissues and caused detectable inﬂammation. In mice deﬁcient
in STAT1-dependent interferon (IFN) responses, CHIKV-LR caused signiﬁcant swelling of the inoculated and
contralateral limbs and dramatic inﬂammatory lesions, while CHIKV-181/25 vaccine and another arthrito-
genic alphavirus, Sindbis, failed to induce swelling. IFN responses suppressed CHIKV-LR and CHIKV-181/25
replication equally in dendritic cells in vitro whereas macrophages were refractory to infection independently
of STAT1-mediated IFN responses. Glycosaminoglycan (GAG) binding may be a CHIKV vaccine attenuation
mechanism as CHIKV-LR infectivity was not dependent upon GAG, while CHIKV-181/25 was highly dependent.
© 2012 Elsevier Inc. All rights reserved.Introduction
First recognized in 2005, a pandemic of mosquito-borne chikungu-
nya (CHIK) fever of unprecedented magnitude has been afﬂicting in-
habitants of the Indian Ocean territories. An estimated six million
people have been infected in a large geographic area encompassing
the East-African equatorial coasts, the Indian Ocean islands of La
Réunion,Madagascar, Mauritius and the Seychelles, most of the Indian
peninsula, Singapore, and Thailand (Powers, 2010; Staples et al.,
2009). Many CHIK fever cases have been diagnosed in travelers
returning home to Europe and the Americas from known outbreak
areas (Tilston et al., 2009). In Southern Italy and France, local disease
transmission has resulted, controlled by intensive mosquito abate-
ment (Gould et al., 2010; Nicoletti et al., 2008; ProMED-mail, 2011).
Since 2006, 106 laboratory-conﬁrmed CHIK cases have occurred in
the United States and public health ofﬁcials have been warned to be
vigilant for evidence of local transmission by indigenous mosquitoes;
however to-date all cases appear to be travel-associated (Gibney et al.,., Pittsburgh, PA 15261, USA.
s, St. Jude Children's Research
rights reserved.2011). Disturbingly, chikungunya virus (CHIKV), the etiologic agent of
CHIK fever, has adapted to allow transmission by amore promiscuous-
ly biting mosquito vector, Aedes albopictus (Reiter et al., 2006), by the
mutation of a single amino acid in the E1 envelope protein (Tsetsarkin
et al., 2007, 2009). This has facilitated human–mosquito–human
spread without the necessity for non-human primate (NHP) reservoir
hosts and lifted a major restriction on endemic establishment.
CHIKV, an enveloped positive-sense RNA virus in the genus Alpha-
virus, family Togaviridae, was ﬁrst isolated during an explosive epi-
demic in Tanzania in 1952. Infection is characterized by the abrupt
onset of fever, headache and skin rash, almost invariably accompa-
nied by excruciating myalgia and polyarthralgia with swollen ankles,
knees and wrists (Powers and Logue, 2007). Higher viremic titers in
the acute phase have been associated with lymphopenia, monocyto-
penia, neutrophilia, CD8+ T cell activation and higher level induction
of inﬂammatory cytokines including interferon-alpha (IFN-α) and
IFN-γ (Ng et al., 2009; Wauquier et al., 2011). Although infection
is usually self-limiting and patients recover within 2 weeks, painful
polyarthralgia can persist long after other symptoms disappear, shifting
from joint to joint with possible post-illness destructive arthropathy
(Brighton and Simson, 1984). Chronic polyarthralgia is associated
with elevated serum IL-6 and GM-CSF (Chow et al., 2011). CHIK fever
is rarely fatal in the absence of underlying complications, but the
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observed in infected children, associated with neurologic sequelae and
occasional mild to severe hemorrhagic manifestations (Brighton and
Simson, 1984; Halstead et al., 1969a, b; Nimmannitya et al., 1969).
Although no licensed vaccine is available, a live-attenuated CHIKV
vaccine candidate was produced two decades ago at USAMRIID by per-
forming 18 serial passages of wild-type CHIKV-15561 strain on human
MRC-5 ﬁbroblasts (Levitt et al., 1986). CHIKV-181/25 (TSI-GSD-218)
was selected as the vaccine seed based upon homogeneous small-
plaque phenotype, avirulence in suckling mice, reduced viremia in
NHPs, and genetic stability. Furthermore, a pilot lot of the vaccine elicited
neutralizing antibody, and protected mice and NHPs against challenge
(Levitt et al., 1986). Except for transient arthralgia in approximately 8%
of human vaccinees, this live-attenuated vaccine was safe, produced
well-tolerated side-effects, andwas highly immunogenic in Phase II clin-
ical trial (Edelman et al., 2000). However, the molecular mechanism(s)
underlying attenuation have not been deﬁned.
Many years after CHIKV pathogenesis was ﬁrst studied in rodents
(Weiss et al., 1965), investigators have revisited murine models of
CHIKV infection and disease in response to the ongoing pandemic to
understand the pathophysiology of CHIKV infection and reveal deter-
minants of disease severity and attenuation. The susceptibility of im-
munocompetent mice to wild-type CHIKV is strongly age-dependent,
reminiscent of studies with wild-type strains of related arthritogenic
Old World alphaviruses, Sindbis (SINV; (Klimstra et al., 1999; Ryman
et al., 2007a)), Semliki Forest (SFV; (Fleming, 1977)), and Ross River
(RRV; (Seay et al., 1981)). Neonatal mice are highly susceptible
to CHIKV-induced fatality (Couderc et al., 2008; Weiss et al., 1965;
Ziegler et al., 2008), but as mice mature average survival times
(ASTs) and survival rates quickly rise (Couderc et al., 2008; Ziegler
et al., 2008). Similar to SINV (Ryman et al., 2000, 2007b) and SFV
(Fragkoudis et al., 2007), STAT1-dependent type I interferon (IFN-α/β)
responses protect adult mice from fatal CHIKV infection initiated by
peripheral inoculation (Couderc et al., 2008; Schilte et al., 2010).
However, these severe, fatal infections likely have little relevance
to the majority of CHIK fever and polyarthritis/polyarthralgia cases
in humans.
It has recently been shown that adult (six-week-old) C57BL/6 mice
develop mild musculoskeletal inﬂammatory disease following wild-
type CHIKV infection with some striking similarities to human infection
(Gardner et al., 2010). Moreover, younger C57BL/6 animals (two-
week-old) develop more severe inﬂammatory disease, with evidence
of arthritis, tenosynovitis and myositis, and viral persistence (Morrison
et al., 2011). Here, we demonstrate for the ﬁrst time that clinical signs
of CHIKV-induced musculoskeletal disease are tremendously exacerbat-
ed in the absence of STAT1-dependent and type I IFN receptor signaling-
dependent responses, leading to polyarthritis/myositis, with edema in
the hind limbs, correspondingly increased CHIKV replication in joint-
associated tissues, tissue pathology and inﬂammatory cell inﬁltra-
tion. Interestingly, severe inﬂammatory disease manifestations are
speciﬁc to wild-type CHIKV infection and not observed in animals
infected with SINV or with the live-attenuated CHIKV-181/25 vaccine
strain, suggesting a pathology speciﬁc to wild-type CHIKV infection.
Our ﬁndings support the contention that relative IFN-α/β response
deﬁciency may underlie severity of human articular disease, wheth-
er the result of host genetics or the virus' ability to evade/antagonize
IFN-α/β responses (Fros et al., 2010).
Although clinical signs of CHIKV-181/25 infection become more
severe in the absence of STAT1-dependent IFN responses, increased
sensitivity to IFN-mediated antiviral responses does not appear to
be the primary mechanism of severe inﬂammatory disease ameliora-
tion as proposed by Partidos et al. (2011). Instead, we propose that
the acquisition of positive-charge mutation(s) in the E2 glycoprotein
leading to glycosaminoglycan (GAG)-mediated cell-surface attach-
ment may, at least in part, underlie amelioration of musculoskeletal
disease, inﬂammatory pathologies, and virus replication.Results
STAT1-dependent IFN signaling is critical for protection of mice against
wild-type CHIKV infection, but not for attenuating the CHIKV-181/25
vaccine strain
Innate immune responses, particularly those mediated by type I
IFN, are known to be pivotal for the protection of mice against fatality
following peripheral inoculation of wild-type Old World alphaviruses
(Ryman and Klimstra, 2008), including SINV (Ryman et al., 2000,
2002, 2007b), SFV (Fragkoudis et al., 2007) and CHIKV (Couderc et
al., 2008; Schilte et al., 2010). To further investigate this phenomenon
and extend the observations to type II IFN responses, we compared
the independent and combined ability of IFN-α/β and IFN-γ receptor-
mediated signaling to protect mice from morbidity and mortality
caused by wild-type CHIKV. Two cDNA clone-derived, minimally
cell culture-passaged, CHIKV strains were used: CHIKV-LR (from a trav-
eler returning from La Réunion, 2006; Tsetsarkin et al., 2006) and
CHIKV-37997 (from a Senegalese mosquito, 1983; Vanlandingham et
al., 2005), to ensure the phenotype observed was not virus strain-
dependent. Groups of eight-week-old controlmice (WT129),mice lack-
ing receptors for IFN-α/β (A129), IFN-γ (G129) or both IFNs (AG129),
ormice deﬁcient in the STAT1 signal transduction factor involved in sig-
naling of both type I and type II IFN responses (STAT129)were inoculat-
ed subcutaneously in one hind-leg footpad with 103 plaque-forming
units (pfu) of either CHIKV-LR or CHIKV-37797 virus (Fig. 1). Inbred,
immunocompetent WT129 mice exhibited no mortality (Figs. 1A–B)
or clinical signs of infection (Figs. 1D–E) following inoculation with
either virus. Furthermore, although Gardner et al. (2010) showed
that IFN-γ is rapidly induced in CHIKV-infected mice, in the absence
of IFN-γ signaling, G129 mice remained resistant to CHIKV-induced
morbidity/mortality and were indistinguishable from WT129 controls
(Figs.1A–B; D–E).
In striking contrast, A129 mice lacking IFN-α/β receptor-mediated
signaling were highly susceptible to infection with either CHIKV-LR
(Fig. 1A) or CHIKV-37997 (Fig. 1B), consistent with the results obtained
by Couderc et al. for the biological CHIKV-LR isolate (Couderc et al.,
2008). These animals displayed clinical signs of illness within
2 days post-infection (d p.i.) including lethargy, rapid weight loss
(Figs. 1D–E), hunched posture, rufﬂing of the fur, and generalized
cachexia. CHIKV-infected A129 mice deteriorated quickly, typically
reaching euthanasia criteria within 4 d p.i. We further showed that
the combined lack of type I and II IFN receptor-mediated signaling
in AG129 mice signiﬁcantly reduced the AST (pb0.05 versus A129;
Figs.1A–B), suggesting a compensatory role for IFN-γ in the absence of
IFN-α/β, similar to our prior observations for SINV infection (Ryman
et al., 2007b). Interestingly, mice deﬁcient in STAT1-dependent IFN
responses had a signiﬁcantly extended AST (pb0.005 versus A129
or AG129), surviving several days beyond CHIKV-infected A129 or
AG129 animals, but eventually reached euthanasia criteria around 7 d
p.i. (Figs. 1A–B; D–E). We infer that substantial IFN-mediated anti-
CHIKV activity remains in the STAT129 animals, although the STAT1-
dependent IFN-α/β responses are critical for protection. No clinical
signs of neurologic disease were apparent even in moribund animals.
To determine the contribution of STAT1-dependent IFN signaling
to the attenuation of the CHIKV-181/25 vaccine strain, eight-week-
old WT129, A129, and STAT129 mice were infected with 103 pfu of
CHIKV-181/25 subcutaneously in the hind footpad. No mortality
(Fig. 1C), weight loss (Fig. 1F), or rufﬂing of the fur were observed
in CHIKV-181/25-infected WT129 or A129 mice. Interestingly,
STAT129 and AG129mice were more susceptible to CHIKV-181/25 in-
fection than the A129 mice with substantial weight loss in all infected
mice (Fig. 1F) and 50% or 100% mortality rates, respectively (Fig. 1C).
The AST of CHIKV-181/25-infected STAT129 and AG129 mice that suc-
cumbed to infection was signiﬁcantly extended compared to mice
infected with wild-type CHIKV (pb0.005), corresponding to a 1–2 day
Fig. 1.Morbidity and mortality following subcutaneous infection of IFN-deﬁcient mice with wild-type or live-attenuated CHIKV strains. WT129 (solid line/open circle); G129 (solid
line/open diamond); A129 (dotted line/gray circle); AG129 (dot-dash line/closed diamond); STAT129 (dashed line/closed circle) mice were inoculated subcutaneously in the hind
foot-pad with 103 pfu of CHIKV-LR (A and D), CHIKV-37997 (B and E) or CHIKV-181/25 (C and F). Percent survival was calculated (A–C) and daily weight change was plotted (D–F)
as an indicator of morbidity (percent weight change compared to day 0). n=4 or 5 mice per treatment group and data are representative of two to three independent experiments.
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181/25 vaccine strain is attenuated primarily by mechanism(s) inde-
pendent of IFN-α/β sensitivity; however, the severity of this virus
infection is increased in the absence of STAT1-dependent IFN path-
ways in our studies and even further in the combined absence of
IFN-α/β and IFN-γ receptor-mediated signaling in keeping with the
observations of Partidos et al. (2011), implicating IFN-γ in protection
from lethality primarily via STAT1-dependent pathways in the ab-
sence of IFN-α/β activity.Disruption of STAT1-dependent type I IFN-mediated responses exacer-
bates joint-associated swelling following wild-type CHIKV-LR infection
It has been previously reported that six-week-old C57BL/6 mice
develop a mild swelling of the ipsilateral (inoculated) hind footpad
following subcutaneous inoculation with wild-type CHIKV (Gardner
et al., 2010), with increased severity in younger animals (Morrison
et al., 2011). However, no swelling of the contralateral hind footpad
was detectable in either study. Perhaps not unexpectedly, we detected
no swelling in the ipsilateral or contralateral hind footpads of eight-
week-old WT129 or G129 mice following subcutaneous inoculation
with CHIKV-LR (Fig. 2B). However, in infected A129 mice swelling
commenced within 24 h p.i. in the inoculated footpad, progressing
to involve the entire hind limb (Fig. 2B) including the toe, ankle, and
knee joints. Moreover, contralateral footpads in CHIKV-LR-infected
A129 animals were signiﬁcantly swollen by 48 h p.i. compared with
the mock-inoculated footpads of uninfected controls (Fig. 2C). CHIKV-
LR-infected STAT129 mice developed swelling of the ipsilateral
(Figs. 2A and B) and contralateral (Fig. 2C) hind limbs with similar
kinetics to the A129 mice, persisting until these animals reached
euthanasia criteria. In both CHIKV-LR-infected A129 and STAT129
mice, the swelling appeared to cause considerable discomfort, evi-
denced by altered gait and reduced tendency to grip with the hind
feet, suggestive of a polyarthralgia. CHIKV-37997 infections were indis-
tinguishable from CHIKV-LR (data not shown). To our knowledge, this
is theﬁrst description of disseminatedCHIKV-induced joint inﬂammationand signs of polyarthralgia in mice, progressing beyond the inoculated
limb and more accurately reproducing human symptoms.
In terms of morbidity and mortality, the virulence phenotype of
another arthritogenic Old World alphavirus, SINV, in IFN-deﬁcient
mice (Ryman et al., 2000, 2005), is very similar to our ﬁndings for
CHIKV. To determine whether or not fatal SINV infection of A129 or
STAT129 mice was associated with arthralgia, we inoculated these
mice with 103 pfu of wild-type SINV strain TR339 subcutaneously in
the hind footpad. TR339 infection caused no detectable hind footpad
swelling in the infected mice, although mice rapidly lost weight and
infection was fatal within 3–4 d p.i. (data not shown). Thus, joint-
associated swelling is not a ubiquitous trait of severe Old World
alphavirus infection in the IFN-deﬁcient models, but is speciﬁc to
CHIKV infection, whereas lethality is common to different virus infec-
tions (Couderc et al., 2008; Fragkoudis et al., 2007; Ryman et al., 2000,
2005) and likely disconnected from severity of arthropathy.
To determine whether the attenuated phenotype of the CHIKV-
181/25 vaccine strain in IFN-deﬁcient animals extends to ameliora-
tion of clinical signs of joint inﬂammation and musculoskeletal dis-
ease in mice, the hind footpads of CHIKV-181/25-infected WT129,
A129 and STAT129 mice were monitored. As observed in WT129
mice infected with wild-type CHIKV, no clinical signs of arthralgia
were detectable in CHIKV-181/25-infected WT129 mice (Fig. 2D). In
contrast to wild-type infection, no evidence of hind footpad swelling
was measurable in CHIKV-181/25 infection of A129 or STAT129 mice
and only mild swelling was observed in CHIKV-181/25-infected
AG129 animals, including those STAT129 and AG129 animals for
which the infection was fatal (Fig. 2D). From these data we infer
that selection of the CHIKV-181/25 vaccine strain by MRC-5 ﬁbroblast
passage has dramatically attenuated the tendency to cause swelling
of the limbs, and that altered sensitivity to IFN responses is not
responsible for this phenotype. Furthermore, we found that three
weeks after “immunization” with CHIKV-181/25, A129 and surviving
STAT129 mice were completely protected not only against general-
ized morbidity and death following subcutaneous challenge with
103 pfu CHIKV-LR in the hind footpad, but also against the develop-
ment of disseminated joint swelling.
Fig. 2. Hind limb swelling following subcutaneous infection of IFN-deﬁcient mice with
wild-type or live-attenuated CHIKV strains. WT129 (white bar); A129 (gray bar); AG129
(hatch bar); and STAT129 (black bar) mice were inoculated subcutaneously in one hind
foot-pad (ipsilateral) with 103 pfu of CHIKV-LR (A, B and C) or CHIKV-181/25 (A and D).
Ipsilateral footpads of mock- and virus-infected STAT129 mice were photographed (A).
Swelling in ipsilateral (B) and contralateral (C) footpads of CHIKV-LR-infected mice and
ipsilateral footpads of CHIKV-181/25-infected mice (D) was measured with calipers
(width×height=area) and calculated as fold-change from preinfection area±standard
deviation (SD). Cross symbol indicates that animals had died prior to this time-point.
*pb0.05; **pb0.01 compared to mock-inoculated, uninfected control. n=4 or 5 mice per
treatment group and data are representative of two to three independent experiments.
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and/or STAT1-dependent IFN response deﬁcient mice
In hind limb sections from the infected limbs of eight-week-old
WT129 mice at 5 d p.i., CHIKV-LR-infected and CHIKV-181/25 vaccine-
infected animals showed little evidence of edema or other gross
inﬂammatory changes in comparison with mock-infected animals
(Figs. 3A–C). This was consistent with the lack of detectable swelling
after footpad measurement (Fig. 2B). However, with CHIKV-LR-
infected WT129 animals, occasional polymorphonuclear and mono-
nuclear inﬁltrates were observed in the hypodermis and associated
with skeletal muscle and tendons (Fig. 3C). After infection of
STAT129 mice, the vaccine strain caused slight thickening of the
dermis with mild edema (Fig. 3D versus E), minor protein (likelyﬁbrin) deposition limited to the hypodermis (Fig. 3H) and marked
inﬁltration of polymorphonuclear and mononuclear cells into the
dermis, hypodermis, peri-muscle and peri-tendon areas (Figs. 3E
and H). Notably, CHIKV-LR-infected STAT129 animals exhibited
edema and striking, disseminated protein deposition in the dermis,
hypodermis, and underlying tissues associated with inﬂammatory
cell inﬁltration (Figs. 3F and I). Erythrocytes were often observed in
the protein depositions indicative of local hemorrhage. Interestingly,
the inﬂammatory cell inﬁltration in CHIKV-181/25-infected STAT129
mice appeared to be similar (Figs. 3E versus F) or perhaps greater
(Fig. 3H versus I) than that observed with CHIKV-LR, yet swelling
was undetectable by morphometric analysis (Fig. 2D) and edema/
protein deposition was very mild. Finally, unlike similar studies
using younger C57BL/6 mice sampled at 7 d p.i. (Gardner et al.,
2010; Morrison et al., 2011), inﬁltration of mononuclear cells into
associated skeletal muscle was not readily observable with any treat-
ment, suggesting that maximal edema occurs in STAT129 animals
in the absence of or prior to frank myositis. These analyses indicate
that the CHIKV-181/25 strain elicits a robust inﬂammatory inﬁltrate
into the infected limb; however, this is not associated with detect-
able swelling. In contrast, swelling due to CHIKV-LR is associated
with inﬂammatory cell inﬁltration, dramatic protein deposition,
and edema.
STAT1-dependent type I IFN responses control the replication and
dissemination of wild-type CHIKV in mice
Since type I, and to a lesser extent type II, IFNs control replication
and dissemination of Old World alphaviruses (Couderc et al., 2008;
Fragkoudis et al., 2007; Ryman et al., 2000, 2002, 2005; Schilte et
al., 2010), we reasoned that the increased susceptibility of IFN-
deﬁcient A129 and STAT129 mice to wild-type CHIKV infection
would correspond to more rapidly disseminated, higher titer virus,
and potentially to altered virus tropism compared with infection of
less susceptible WT129 mice. WT129, A129, and STAT129 mice were
inoculated subcutaneously with 103 pfu CHIKV-LR in each hind foot-
pad. Infectious viral titers were measured by plaque assay of serum
and PBS-perfused tissues at various times p.i. to establish the kinetics
and extent of replication and dissemination (Fig. 4). In subclinical
infection of WT129 mice, early CHIKV-LR replication in the popliteal
lymph node, draining the inoculation site (DLN), was followed by a
low-level serum viremia and disseminated replication in peripheral,
and subsequently CNS, tissues. Virus replicated most efﬁciently in
muscle (Fig. 4E), but WT129 mice were able to control and clear the
infection from all tissues within 120 h p.i.
In the absence of IFN-α/β receptor-mediated antiviral responses,
CHIKV replication and dissemination were poorly controlled, with
signiﬁcantly higher levels of replication in the DLN by 48 h p.i.
(Fig. 4A), correspondingly higher serum viremia (Fig. 4B), and rapid
seeding of tissues in the lymphoid compartment, including spleen
and liver (Figs. 4C and D, respectively) and musculoskeletal compart-
ment including gastrocnemius muscle, bone epiphyses and aspirate
marrow (Figs. 4E, F and G, respectively), demonstrating tropism sim-
ilar to human disease (Ozden et al., 2007). Peak replication in mus-
culoskeletal tissues of the hind limb occurred 48 h p.i., coincident
with the onset of severe hind limb swelling. However, although
virus levels in these tissues began to decline after 48 h, swelling
worsened. Titration of spinal cords and whole brain homogenates
revealed exponential virus replication in the absence of IFN-α/β
receptor- or STAT1-dependent signaling without evidence of con-
trol/clearance (Figs. 4H and I, respectively). Virus replication may
be predominately restricted to the meninges and/or endothelial
cells, sparing the brain parenchyma, as demonstrated by Couderc et
al. (2008). It seems likely that systemic replication and/or CNS infec-
tion are responsible for mortality, disconnected from arthralgic
manifestations.
Fig. 3.Histopathology in CHIKV-infected hind limb tissues. Hematoxylin and eosin stained sections from the footpads of mock-infected (A,D,G), CHIKV-181/25-infected (B, E, H) and
CHIKV-LR-infected (C,F,I) WT129 (A–C) and STAT129 (D–I) mice. Within panels, bone (Bo), dermis (De), hypodermis (Hy), muscle/tendon (Mu), edema (Ed), polymorphonuclear
cells (arrowheads), and mononuclear cells (arrows) are indicated. Original magniﬁcation was 200× (A–F) or 100× (G–I). n=3 mice per treatment group.
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Reasoning that reduced ability of the CHIKV-181/25 vaccine to
replicate and disseminate in mice may contribute to the ameliora-
tion of hind limb swelling, WT129, A129, and STAT129 mice were
inoculated subcutaneously with 103 pfu of either CHIKV-LR or
CHIKV-181/25 in each hind footpad and infectious viral titers
were determined in serum and PBS-perfused tissues 48 h p.i. This
time-point was selected as peak titers were measured in CHIKV-
LR-infected mice above. In WT129 infected mice, CHIKV-181/25
replication was greatly reduced compared to CHIKV-LR, with virus
titers below the limit of detection for serum and all tissues except
DLN and muscle (Fig. 5A). Interestingly, CHIKV-LR and CHIKV-
181/25 titers in the DLNs of A129 and STAT129 mice (Figs. 5B and
C, respectively), were within 10-fold, suggesting that these viruses
spread from the site of inoculation and seed the DLN similarly, but
differ in their ability to fuel a serum viremia and disseminate sys-
temically. CHIKV-181/25 replication in the tissues of A129 and
STAT129 mice was similar at 48 h p.i. (p>0.05), although mortality
differed tremendously, suggesting that CNS replication at later
times may be signiﬁcantly different. Overall, it is evident that IFN-
α/β receptor-mediated antiviral responses dramatically retard the
replication and dissemination of both the wild-type and vaccine vi-
ruses, primarily via STAT1-dependent pathways. However, STAT1-
dependent IFN response deﬁciency only restores CHIKV-181/25
vaccine replication to levels equivalent to CHIKV-LR infection of
WT129 mice. Thus, the reduced replication potential of CHIKV-
181/25 in peripheral tissues may be responsible, either directly or
indirectly, for the lack of hind limb swelling and inﬂammation,and is largely independent of IFN sensitivity. However, STAT1-
dependent host responses are important for protection from
lethality.STAT1-dependent responses determine the permissivity of dendritic cells,
but not macrophages, to CHIKV-LR and CHIKV-181/25 infection
To determine whether or not wild-type CHIKV-LR and CHIKV-181/
25 vaccine strains differ in their ability to infect myeloid dendritic
cells (mDCs) and macrophages, to assess the relative contribution
of the STAT1-dependent IFN response to permissiveness of these
cells to the wild-type versus vaccine virus, primary bone marrow-
derived mDCs and macrophages from WT129 and STAT129 mice
were infected at low multiplicity (0.1 pfu/cell). As anticipated, nei-
ther virus replicated efﬁciently within WT129-derived mDCs, but
STAT1-deﬁcient mDCs were highly permissive to both (Fig. 6A), sug-
gesting that mDCs are protected from CHIKV by inherent and/or in-
duced STAT1-dependent IFN responses and that attenuation of the
CHIKV-181/25 vaccine does not correlate with increased sensitivity
to or induction of IFN responses in vitro. Interestingly, neither virus
replicated above input levels in immature (3 d-cultured; Fig. 6B) or
mature (7 d-cultured; Fig. 6C) macrophages, even in the absence of
STAT1, or in the RAW264.7 monocyte/macrophage cell line
(Fig. 6D). These data further support our contention that ameliora-
tion of arthralgic disease in CHIKV-181/25-infected STAT129 mice
is not due to increased IFN sensitivity/induction, but also suggest
that increased permissivity of STAT1-deﬁcient DCs to CHIKV replica-
tion in vitro is not necessarily correlated with the development of
inﬂammatory disease.
Fig. 4. Replication in IFN-deﬁcient mice infectedwith CHIKV-LR.WT129 (open square), A129 (closed triangle), and STAT129 (closed circle)micewere inoculated subcutaneously in both
foot-pads with 103 pfu of CHIKV-LR. Infectious virus titers in sera and PBS-perfused tissue homogenateswere determined by standard plaque assay on BHK-21 cells and presented as pfu/
DLN, mL (sera and bone aspirate) or g (all other tissues)±SD. *pb0.05; **pb0.01; - p>0.05 for WT129 versus A129/WT129 versus STAT129. n=3mice per treatment group and time-
point.
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glycosaminoglycan-dependence for infectivity
Recently, we have demonstrated that wild-type strains of enceph-
alitic NewWorld alphaviruses exhibit varying degrees of dependency
upon cell-surface glycosaminoglycan (GAG), heparan sulfate (HS), for
infectivity. In contrast, the infectivity of wild-type Old WorldFig. 5. Comparative replication in IFN-deﬁcient mice infected with CHIKV-LR or CHIKV-181/2
foot-pads with 103 pfu of CHIKV-LR (black bar) or CHIKV-181/25 (white bar; hatching indic
tissue homogenates harvested 48 h p.i. were determined by standard plaque assay on BHK-2
SD. *pb0.05; **pb0.01; - p>0.05 for CHIKV-LR versus CHIKV-181/25/ versus WT129. n=3alphaviruses, including CHIKV-LR, is almost entirely HS-independent
(Gardner et al., 2011). Since HS binding can be conferred upon Old
World alphaviruses by adaptation to cell culture and the accumula-
tion of positively charged amino acid substitutions in the E2 envelope
glycoprotein (Heil et al., 2001; Klimstra et al., 1998; Smit et al., 2002;
Zhang et al., 2005), resulting in attenuation in vivo (Byrnes and
Grifﬁn, 1998, 2000; Klimstra et al., 1999; Ryman et al., 2000), we5. WT129 (A), A129 (B), and STAT129 (C) mice were inoculated subcutaneously in both
ates titer was below limit of detection). Infectious virus titers in sera and PBS-perfused
1 cells and presented as pfu/DLN, mL (sera and bone aspirate) or g (all other tissues)±
mice per treatment group and time-point.
Fig. 6. CHIKV replication inmyeloid cells. Bonemarrowwas harvested fromWT129 (open
symbols) and STAT129 (closed symbols) mice and differentiated into mDCs (A), 3 d im-
mature macrophages (B), or 7 d mature macrophages (C), and compared to mouse
RAW 264.7 monocyte/macrophage cells (D). Cells were infected at a multiplicity of infec-
tion (MOI) of 0.1 pfu/cell with CHIKV-LR (circles) or CHIKV-181/25 (triangles). Superna-
tant was collected at various times p.i. titered by standard plaque assay. Datum points
are n=3±SD pfu/mL. Dotted line indicates limit of detection.
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wild-type CHO-K1 versus GAG-deﬁcient pgsA745 cells. Whereas the
infectivity of CHIKV-LR was not signiﬁcantly different in the presence
or absence of GAGs, CHIKV-181/25 exhibited a high dependence,
exhibiting a reduction in infectivity of ~90% on GAG-deﬁcient cells
(pb0.0001; Fig. 7A), similar to that observed for HS binding SINV
mutants (Klimstra et al., 1998). Furthermore, sodium chloride (NaCl)
elution, which disrupts virion binding to HS on cell surfaces (Klimstra
et al., 1998) indicated that the CHIKV-181/25 vaccine virus was
effectively eluted by 350 mM salt, whereas the wild-type virus was
not (Fig. 7B).
The genome sequences of CHIKV-LR, CHIKV-181/25 and its parent,
CHIKV-15561 were downloaded, and the E2 protein genes were iden-
tiﬁed and translated (GenBank accession numbers DQ443544.2,
EF452493.1 and L37661.3, respectively). Alignment of the E2 glyco-
protein amino acid sequences revealed that, while there are 15
amino acid differences between wild-type CHIKV-LR and CHIKV-
15561, the CHIKV-181/25 vaccine strain is identical to its parent atFig. 7. Differential dependence of CHIKV infectivity upon ionic interaction and glycos-
aminoglycans for infectivity. Relative infectivity of CHIKV-LR and CHIKV-181/25 on
CHO-K1 (black bars) and pgsA745 GAG-deﬁcient (white bars) cells (A). Relative infectiv-
ity of CHIK-LR and CHIKV-181/25 on CHO-K1 cells in 103 mM (black bars) or 350 mM
(white bars) NaCl (B). Percent infection was normalized to infectivity on CHO-K1 cells
in RPMI1640 without added salt (103 mMNaCl). Percent infection was normalized to in-
fectivity on control cells. All datum points are n=3±SD.all of these positions (Table 1). However, two amino acid substitu-
tions have arisen during cell culture passage to make CHIKV-181/25
at E2 position 12 (T to I) and E2 position 82 (G to R), but are con-
served between the wild-type strains. Notably, the E2R82 mutation
increases the net positive-charge of the CHIKV-181/25 E2 glycopro-
tein, coincident with acquisition of GAG-dependent binding in
vitro, reduced replication/dissemination in vivo, and amelioration
of disease.Discussion
The molecular and immunologic mechanisms underlying CHIKV
pathogenesis, virulence and attenuation are not well understood,
impeded by the lack of a robust small animal model of acute and
persisting polyarthritis/polyarthralgia. However, careful analysis of
adult C57BL/6 mice has produced a model for non-fatal CHIKV infec-
tion, where infectious virus is obtained from various tissues, musculo-
skeletal inﬂammatory disease with joint involvement is observed
and proinﬂammatory mediators (IFN-α/β, IFN-γ, MCP-1, TNF-α
andIL-6) are elevated in both acute-phase sera and footpad tissue
(Gardner et al., 2010). Younger C57BL/6 animals (two-week-old) de-
velop more severe inﬂammatory disease, with evidence of arthritis,
tenosynovitis and myositis, and viral persistence (Morrison et al.,
2011). Here, we have investigated the role of IFN responses in amelio-
ration of wild-type CHIKV-induced musculoskeletal disease. We dem-
onstrate for the ﬁrst time that IFN-mediated antiviral responses,
largely dependent upon STAT1-mediated signaling, control the repli-
cation of wild-type CHIKV in muscle and joint-associated tissues of
mice, and coincidentally ameliorate clinical signs of polyarthralgia.
Importantly, we have shown that the disease course in animals deﬁ-
cient in IFN responses when infected subcutaneously with wild-type
CHIKV strains mimics key aspects of severe human disease, such as
virus tropism for bone and joint tissues, edema and indications of ar-
thralgia in multiple limbs, and associated tissue pathologies and in-
ﬂammatory inﬁltrates. These ﬁndings suggest that IFN deﬁciencies
in the human host and/or species-speciﬁc evasion/antagonism of
IFN responses by the virus would likely exacerbate musculoskeletal
disease.
In order to directly combat antiviral activity or to subvert the tran-
sition from innate to adaptive immunity, pathogenic alphaviruses
have evolved to evade and/or antagonize the IFN-α/β responses
(Burke et al., 2009; Fros et al., 2010; Gardner et al., 2008; Simmons
et al., 2009; Yin et al., 2009) and resistance of a given alphavirus to
the IFN response appears to be a critical virulence determinant
(Couderc et al., 2008; Fragkoudis et al., 2007; Gardner et al., 2009;
Ryman et al., 2000; Schilte et al., 2010; White et al., 2001). Central
to this study is the ﬁnding that sensitivity of CHIKV to murine IFN-
mediated antiviral responses is sufﬁcient to protect against disease,
while deﬁciency in the IFN response leads to severe polyarthralgia
with similarities to human CHIK fever. In contrast, virulent human in-
fections presumably occur in individuals with properly functioning
IFN responses. The apparent difference in efﬁcacy between human
and murine STAT1-dependent IFN-α/β responses against CHIKV in-
fection implies species-speciﬁcity, such that human IFN responses
are signiﬁcantly less effective than murine in ameliorating disease,
at least in symptomatic infections. Alternatively, CHIKV may have
evolved mechanisms to circumvent/antagonize IFN responses in
natural primate hosts which are less effective in mice. Interestingly,
CHIKV nsP2 has been shown to inhibit JAK-STAT signaling-dependent
type I and II IFN responses in primate-derived Vero cells (Fros et al.,
2010), presumably allowing the virus to overcome or circumvent
STAT1-dependent responses in vivo,whichmay contribute to enhanced
virulence in primates over rodents if this ability proves to be species-
speciﬁc. Furthermore, CHIKV globally inhibits translation of cellular
mRNAs in highly permissive primate-derived cells, blunting IRF3-
Table 1
Amino acid differences in the E2 glycoprotein sequences of wild-type and live-attenuated CHIKV strains.
Virus strain E2 amino acid position (numbered from N-terminus)
2 12 82 118 149 157 164 194 205 255 312 317 318 375 377 384 386
CHIKV-LR T T G S K V T G G I M V V T I M A
CHIKV-15561 I T G G R A A S D V T I R S V V V
CHIKV-181/25 I I R G R A A S D V T I R S V V V
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ble antagonism/evasion strategies have not yet been investigated.
In the absence of STAT1-dependent IFN responses, wild-type
CHIKV infection led to rapid viral dissemination, most likely by infect-
ing and commandeering migratory DCs, as described for other alpha-
viruses (Ryman et al., 2000, 2005). CHIKV-LR ampliﬁed in the DLN,
seeded a serum viremia and spread to other tissues, notably exhibit-
ing a strong tropism for muscle and joint-associated tissues. In particu-
lar,muscle, bone epiphyse, and bonemarrowwere sites of replication in
STAT129 mice and exhibit extensive pathology, generally consistent
with previously published studies (Gardner et al., 2010; Morrison et
al., 2011), with two notable exceptions. First, myositis was greatly re-
duced in our studies although edema was far more severe, presumably
due to differences inmouse strain, age (twoweeks older), or time-point
(5 d p.i. versus 7 d p.i.). However, myositis is infrequently described in
CHIKV-infected humans (Ozden et al., 2007). Second, striking deposi-
tion of protein in the dermis, hypodermis, and underlying tissues
was associated with inﬂammatory cell inﬁltration and hemorrhage in
CHIKV-LR-infected STAT129 mice.
Subcutaneous infection of A129 and STAT129 mice readily distin-
guishes virulent wild-type CHIKV infection from the live-attenuated
CHIKV-181/25 vaccine strain, with “vaccination” providing protection
against fatality following wild-type challenge, consistent with the
ﬁndings of Partidos et al. (2011) and also against swelling of the
limbs. Attenuated CHIKV-181/25 vaccine virus infection of STAT129
and A129 animals was correlated with partial to complete attenuation
compared to wild-type CHIKV-LR, with reduced joint-associated repli-
cation and pathology, although inﬂammatory cell inﬁltration was
comparable or possibly superior to wild-type infected mice. Thus, the
pathogenesis of CHIKV-181/25 was dramatically restricted compared
with the wild-type virus even in the absence of STAT1-dependent
IFN activity, fromwhichwe infer that the primary mechanism underly-
ing CHIKV-181/25 attenuation is not increased sensitivity to the IFN
response, although IFN-γ responses may contribute. In keeping
with this interpretation, the sensitivity of the wild-type and vaccine
strain to STAT1-dependent IFN responses in primary DCs was
indistinguishable.
We and others have shown previously that: i) wild-type Old
World alphaviruses including wild-type strains of CHIKV-LR do not
bind to cells via HS (Gardner et al., 2011; Heil et al., 2001; Klimstra
et al., 1998; unpublished data); ii) HS binding capability is rapidly ac-
quired by these viruses as a cell culture-adaptive mechanism during
in vitro passage by the accumulation of positively charged amino
acid substitutions in the E2 envelope glycoprotein (Heil et al., 2001;
Klimstra et al., 1998; Smit et al., 2002; Zhang et al., 2005); and iii)
this typically results in attenuation in vivo due to sequestration of
virus in tissues (Byrnes and Grifﬁn, 1998, 2000; Klimstra et al.,
1999; Ryman et al., 2000). E2 amino acid sequence comparison
revealed that in vitro passage of wild-type CHIKV to create the
CHIKV-181/25 vaccine resulted in two amino acid substitutions in
the E2 attachment protein, one of which increases the net positive-
charge (E2R82). Moreover, we showed that the vaccine strain is high-
ly dependent upon GAGs for infectivity in vitro. We propose that GAG
(most likely HS) binding may be an attenuating mechanism in the
CHIKV-181/25 strain, mediated by the E2R82 mutation, restricting vi-
remic potential and dissemination beyond the DLN, and attenuating
disease. Consistent with this idea, we have demonstrated previouslythat an equivalent HS-binding SINV mutant remains attenuated
even in the absence of IFN-α/β responses (Ryman et al., 2000). The
contribution to attenuation of individual CHIKV-181/25 mutations
in E2 and other viral proteins is currently being investigated.
Overall, we propose that CHIKV infection of IFN-deﬁcient mice
provides a valuable small animal model, exhibiting key features of
severe human CHIKV infection, in which to evaluate contributions
of virus and host genetics to virulence/attenuation and protection,
and in which to test candidate vaccines and therapeutics without lim-
itations of host age. We are exploring the possibility that wild-type
CHIKV evades/antagonizes IFN responses by species-speciﬁc mecha-
nisms to further reﬁne this model.Materials and methods
Mice
Wild-type 129 Sv/Ev (WT129) and STAT1 deﬁcient (STAT129)
mice were purchased from Taconic laboratories. Mice deﬁcient in re-
ceptors for IFN-α/β (A129), IFN-γ (G129) or both (AG129) were bred
in-house. All mice were housed under speciﬁc pathogen-free condi-
tions, and used at 8 weeks of age. Experiments were conducted in ac-
cordance with Institutional Animal Care and Use Committee policies
at Louisiana State University Health Sciences Center at Shreveport
and the University of Pittsburgh.Cell lines and primary cell cultures
Baby hamster kidney cells (BHK-21; ATCC) were maintained in
alpha minimum essential medium (AMEM) supplemented with 10%
donor bovine serum (DBS) and 10% tryptose phosphate broth. Murine
RAW264.7 monocyte/macrophages were maintained in Dulbecco's
modiﬁed Eagle's medium (DMEM) supplemented with 10% fetal bo-
vine serum (FBS). Chinese hamster ovary cells (CHO-K1) and CHO-
K1 cells deﬁcient in all glycosaminoglycans including HS (pgsA-745)
were maintained in Ham's F12 supplemented with 10% FBS. All
media for cell lines also contained penicillin (100 U/mL), streptomy-
cin (0.05 mg/mL) and L-glutamine (0.05 mg/mL).
mDCs and macrophages were generated frommouse bone marrow.
mDCs were cultured as previously described (Gardner et al., 2008).
Brieﬂy, bone marrow aspirated from femurs and tibias was plated
for 1 h (37 °C; 5% CO2) to allow contaminating macrophages to adhere,
after which the non-adherent mDC progenitors were removed and
cultured in RPMI1640 medium supplemented with 10% FBS, 1% nones-
sential amino acids, 100 U/mL penicillin, 0.05 mg/mL streptomycin,
0.05 mg/mL L-glutamine, 1 mM sodium pyruvate, 5 mM HEPES buffer,
50 μM β-mercaptoethanol, 10 ng/mL GM-CSF and 10 ng/mL IL-4
(Peprotech, Rocky Hill, NJ). After 7 d, non-adherent mDCs were pel-
leted, counted and resuspended in supplemented RPMI1640 medium
for infection.
Adherent macrophages from the bone marrow were cultured
for 3 d (immature) or 7 d (mature) in DMEM supplemented with
10% FBS, 20% L929-conditioned supernatant, 10% FBS, 100 U/mL
penicillin, 0.05 mg/mL streptomycin and L-glutamine. Cells were har-
vested by scraping, pelleted, and seeded for infection.
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Stocks of CHIKV-LR and CHIKV-37797 viruses were generated from
genome-length cDNA clones (Tsetsarkin et al., 2006; Vanlandingham
et al., 2005). Low passage strain CHIKV-37997 was isolated from
Senegalese mosquitoes in 1983. The CHIKV-LR strain was isolated
on La Réunion Island during the ongoing epidemic. Brieﬂy, linearized
cDNA templates were used to generate capped infectious viral RNA
by in vitro transcription (mMessage mMachine, Ambion). BHK-21
cells were electroporated with the infectious RNA, and virus particles
were harvested from the supernatant when cytopathic effect (CPE)
was observed, 20–24 h later. The biological CHIKV-181/25 vaccine
strain, also called TSI-GSD-218 (Levitt et al., 1986), was generously
provided by Dr. Scott Weaver (University of Texas Medical Branch,
Galveston, TX) and passed once on BHK-21 cells. For all virus stocks,
cell supernatants were clariﬁed by centrifugation and single-use
aliquots were stored at −80 °C. Titers of virus stocks were deter-
mined by standard plaque assay on BHK-21 cells, expressed as pfu/
mL.
Virus growth curves
All cells were infected at a multiplicity of infection (MOI) of
0.1 pfu/cell. Adherent bone marrow-derived and RAW264.7 macro-
phages were infected in a 24 well plate. After 1 h incubation, cells
were washed with PBS-1% DBS, and appropriate medium was
replaced before cells were incubated (37 °C; 5% CO2). Nonadherent
cells were infected in a 96 well plate 1 h at 37 °C, and then washed
in PBS-1% DBS by pelleting and resuspension. Cells were resuspended
in appropriate medium and seeded into 24 well plates and incubated
(37 °C; 5% CO2). Supernatant was harvested at time zero and subse-
quent times p.i. for titration by plaque assay.
Morbidity/mortality and pathogenesis studies
Mice were injected subcutaneously in the hind footpad using a 27-
gauge needle and 100 μL gas-tight Hamilton syringe with 10 μL of in-
oculum containing 103 pfu of virus in phosphate-buffered saline
(PBS) containing 1% DBS. Mock-infected mice received 10 μL of PBS-
1% DBS by the same route. Mice were scored and weighed daily,
and footpad width and height in the metatarsal region were mea-
sured with calipers where appropriate to calculate area (width×
height) and fold-increase over pre-infection area. AST and percent
mortality were calculated and statistically analyzed.
At predetermined times post-infection (p.i.), groups of three mice
were euthanized under isoﬂuorane anesthesia and blood was collect-
ed by cardiac puncture. Sera were separated from whole blood using
Microtainer tubes (Becton-Dickinson), aliquoted and stored at −
80 °C. Mice were then perfused with PBS-1% DBS for 10 min at
7 mL/min to ﬂush blood-borne virus. Perfused tissues were homoge-
nized in PBS-1% DBS after one freeze–thaw by mechanical disruption
and sedimentation of cell debris. Serum and supernatants from ho-
mogenized tissue were assayed for virus by a standard plaque assay
on BHK-21 cells and titers were expressed as pfu/DLN, mL (sera and
bone marrow aspirate) or g (all other tissues).
Histopathology
Mice were sacriﬁced 5 d p.i., brieﬂy perfused with PBS-1% DBS to
exsanguinate and then with 4% paraformaldehyde (PFA) for 10 min
at 7 mL/min. Hindlimbs were decalciﬁed in 4% PFA containing 10%
EDTA for at least 3 wk before parafﬁn embedding. Five μm thick
H&E-stained sections were viewed on a light microscope (Olympus
CKX41) and pictures were taken with an Olympus DP72 camera
using Olympus CellSens Standard software.Glycosaminoglycan-dependency of infectivity
Virus was diluted in either RPMI1640 or RPMI1640 containing
350 mM NaCl and then used to infect CHO-K1 or GAG-deﬁcient
pgsA745 cells. Cells were incubated for 1 h (37 °C; 5% CO2) before
overlaying with immunodiffusion agarose. At 48 h p.i., cells were
ﬁxed overnight with 4% PFA, after which PFA and overlay were re-
moved and cells were stained for CHIKV antigen. Brieﬂy, cells were
blocked with PBS buffer containing albumin, non-fat milk, Triton X-
100, and normal donkey serum for 1 h at room temperature. Cells
were then stained with CHIKV polyclonal antibody (ATCC) diluted
in supplemented PBS buffer (1 h, room temperature). Primary anti-
body binding was detected by incubation with a ﬂuorescently conju-
gated secondary antibody (donkey anti mouse DyLight 594; Jackson
ImmunoResearch) diluted in supplemented PBS buffer for 1 h at
room temperature in the dark. Infectious foci were then quantiﬁed
on an Olympus CKX41 inverted ﬂuorescent microscope.
Statistical analyses
Statistical signiﬁcance for mortality curves was determined by
Mantel–Cox log-rank test (GraphPad PRISM software) and for other
experiments a two-tailed Student's t test with two-sample equal
variance was used (Microsoft Excel software).
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